Pomerantz Law Firm Launches Investigation into NeuroPace, Inc. Investors' Claims

Pomerantz LLP has initiated an investigation concerning potential claims from investors of NeuroPace, Inc. This scrutiny focuses on whether the company and certain individuals within its management engaged in fraudulent activities relating to securities or were involved in other unlawful business practices. Investors who believe they may have been adversely affected by these actions are encouraged to reach out to attorney Danielle Peyton via email at [email protected] or call 646-581-9980, extension 7980, to discuss their situation and options.

The impetus for this investigation stems from a troubling press release that NeuroPace issued on May 27, 2025. In this announcement, the company reported preliminary one-year results from the two-year NAUTILUS study. This study aimed to evaluate the safety and effectiveness of the RNS System for patients suffering from drug-resistant idiopathic generalized epilepsy (IGE). Unfortunately, the findings revealed that the study did not achieve statistical significance in demonstrating the primary effectiveness endpoint the research sought to prove. Specifically, the expected outcome was to demonstrate a delay in the occurrence of a second generalized tonic-clonic seizure in the group receiving active stimulation compared to the sham stimulation group.

The fallout from this announcement was immediate and severe. On the day of the release, NeuroPace's stock price tumbled by $5.02 per share—roughly 28.39%—closing at $12.66 per share. Such a dramatic decrease underscores the gravity of the situation for investors who may have been misled about the company's performance and the viability of its treatment options.

Pomerantz LLP is recognized as a leading law firm specializing in corporate, securities, and antitrust class action litigation. The firm has garnered a respected reputation over its more than 85 years of operation by advocating for the rights of investors who fall victim to misconduct, securities fraud, and other breaches of fiduciary duty. With offices located in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues to champion the cause of its clients, targeting the recovery of substantial damages in numerous cases associated with class actions.

The firm's founder, the late Abraham L. Pomerantz, is celebrated as a pioneer in the realm of securities class actions and has laid the groundwork for the institution's current mission. Today, the firm carries forward his legacy of defending the interests of those victimized by fraudulent corporate practices.

Conclusion

In light of the significant impact stemming from NeuroPace's findings, investors are urged to act promptly if they feel they have been wronged. The legal surfaces surrounding securities claims can be complex, and Pomerantz LLP's dedicated team is poised to offer the necessary support and expertise. For more detailed information or to explore options for joining any upcoming class action, investors should consider making contact with the firm without delay.

For more information about Pomerantz LLP and their ongoing efforts, feel free to visit their official website at www.pomlaw.com.